logo banner home news contact
space about argos space
argos overview
market opportunities
current investors


Current Investors

Argos Therapeutics is funded by a broad syndicate of top-tier life science investors, including:

The Aurora Funds
Founded in 1994, The Aurora Funds is a venture capital firm that provides capital, connections and strategic help to entrepreneurs with early-stage life science and information technology companies, primarily in the Southeastern and Mid-Atlantic United States. Aurora typically invests in seed and first- round financing opportunities. The firm has more than $155 million of total capital under management and is currently investing out of its fourth fund of $85 million. The firm has the capacity to invest between $4 million and $7 million throughout the life cycle of an investment.

In 2007, Forbion Capital Partners (Forbion) spun out the life sciences venture capital activities of ABN AMRO Capital to form a new, independent venture capital group. Forbion raised a EUR 200 M fund with ABN AMRO and Coller Capital as founding investors. The new fund incorporates the existing life sciences portfolio of ABN AMRO Capital, valued at EUR 90 M.

GeneChem Therapeutics Venture Fund L.P. is fully dedicated to making investments in companies concentrating their research and development efforts in the field of proliferative disorders, e.g. cancer and infectious diseases. This is the second GeneChem fund and it was launched in 2000 with a committed capital of $137 million. It has invested in over 15 companies.

Intersouth Partners
Intersouth is one of the nation’s most experienced early stage venture capital firms, managing more than $500 million in six venture capital partnerships since 1985. As one of the largest early stage firms in the Southeast and Mid-Atlantic regions, it has invested in more than 75 companies, and focuses on the life sciences and information technology sectors.

Lumira Capital
Built on a foundation that leverages 18 years of North American venture capital experience, the Lumira Capital team has been investing in transformational health and life science companies for more than a decade.

TVM Capital, founded in 1983, is one of the first venture capital funds formed in Germany and a leader in transatlantic operations. The German-U.S. venture capital company has offices in Munich and Boston. For many years, TVM has focused on information technology and life sciences, high growth sectors where innovation, effective management and sound financial backing have enormous impact on company growth.

TVM funds have made investments in over 220 technology companies in Europe and the United States. Many of these enterprises went public on U.S. or European stock exchanges or were sold to strategic acquirers.